Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Pro MedicusPMDIY 77 EV-to-EBIT is 130.06 as of Jul. 26, 2026, which is 26% above its 10-year median of 103.22. GuruFocus rates PMDIY with a GF Score™ of 77/100 and a GF Value™ of $40.30 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 471 Healthcare Providers & Services companies, Pro Medicus ranks worse than 92.14% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pro Medicus's Enterprise Value for the quarter that ended in Dec. 2025 was $17,207.1 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $117.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus EV-to-EBIT Related Terms
Pro Medicus EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pro Medicus's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, Pro Medicus's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pro Medicus EV-to-EBIT vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Pro Medicus's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pro Medicus's EV-to-EBIT falls into.
Pro Medicus's current Enterprise Value is $15,260.5 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pro Medicus's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $117.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pro Medicus (PMDIY) has a EV-to-EBIT of 130.06 as of Jul. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pro Medicus and its competitors. This is 26% above median its historical median of 103.22. Over the past decade, Pro Medicus' EV-to-EBIT has ranged from 34.53 to 265.31. According to the industry distribution chart, Pro Medicus ranks #434 out of 471 companies in the Healthcare Providers & Services industry, placing it in the top 92.1%.
Is Pro Medicus' EV-to-EBIT too high?
Pro Medicus' current EV-to-EBIT of 130.06 is 26% above median its 10-year median of 103.22. Over the past 10 years, this metric has ranged from a low of 34.53 to a high of 265.31. The Healthcare Providers & Services industry median EV-to-EBIT is 15.84. Pro Medicus' value of 130.06 is 721.1% above this industry median. Based on the distribution chart, Pro Medicus ranks #434 out of 471 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Pro Medicus has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pro Medicus' EV-to-EBIT compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Pro Medicus ranks #434 out of 471 companies for EV-to-EBIT. This places Pro Medicus in the lower half of its industry. The industry median EV-to-EBIT is 15.84. Pro Medicus' value of 130.06 is 721.1% above this benchmark. Historically, Pro Medicus' own EV-to-EBIT has ranged from 34.53 to 265.31 over the past decade. While the company's 10-year median is 103.22 vs. the industry median of 15.84, Pro Medicus has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Healthcare Providers & Services company?
The median EV-to-EBIT among Healthcare Providers & Services companies is 15.84, based on 471 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pro Medicus's current EV-to-EBIT of 130.06 is 721.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pro Medicus and its competitors. For the Healthcare Providers & Services industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pro Medicus's current EV-to-EBIT is 130.06, which is 26% above median its own 10-year median of 103.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pro Medicus stock overvalued right now?
Based on GuruFocus' analysis, Pro Medicus (PMDIY) is currently considered Modestly Undervalued. The stock's GF Value™ is $40.30, compared to a current price of $29.51 — trading 26.8% below its estimated fair value. The current EV-to-EBIT is 130.06, which is 26% above median its 10-year median of 103.22 and 721.1% above the Healthcare Providers & Services industry median of 15.84. Pro Medicus' overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pro Medicus (PMDIY), the current EV-to-EBIT is 130.06 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pro Medicus (PMDIY) Overvalued in 2026?
Based on GuruFocus' analysis, Pro Medicus stock appears to be undervalued.
The current stock price of $29.51 is trading 26.8% below its estimated GF Value™ of $40.30.
GuruFocus considers Pro Medicus to be Modestly Undervalued.
Key valuation signals for PMDIY:
EV-to-EBIT: 130.06 (26% above median its 10-year median of 103.22)
GF Value™: $40.30 vs. price of $29.51 (26.8% below fair value)
Industry Position: 721.1% above the Healthcare Providers & Services median (#434 of 471)
No single metric tells the full story. See the PMDIY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pro Medicus is a healthcare IT company specializing in radiology imaging software. Its main product, Visage 7, is a clinical desktop application that radiologists use to view, enhance, and manipulate images from any device and make a diagnosis. Its main customers are US private academic hospitals. In fiscal 2025, Pro Medicus earned 90% of revenue in North America, 8% from Australia, and the remaining 2% in Europe.
77GF Score
Get the complete analysis for PMDIY
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PMDIY has been successfully added to your 
